VIR-5103

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameVIR-5103

Drug Alias NameAnti-CCR5 and CXCR4 ribozyme therapy (Viratis)VIR-5100VIR-5103

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > RibozymeCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonistsC-C chemokine receptor type 5 antagonistsHIV fusion inhibitors

TargetsC-C chemokine receptor type 5C-X-C motif chemokine receptor 4

Therapy Area/IndicationsHepatitis BHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesViratis Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesViratis Ltd

Active IndicationsN/A

Inactive IndicationsHepatitis BHIV Infections

Other Information

ATC CodeN/A